ANRG news release:
'Will Test Results Of New Arthritis Drug Cause Stock Price Of Anergen Inc. To
Explode?' Asks GHLstockalert
OCALA, Fla., July 8 /PRNewswire/ -- Anergen Inc. (Nasdaq: ANRG - news) was chosen today by GHLstockalert as ''the most likely small-cap,
bio-tech company whose stock is a timebomb that could literally explode in price in the immediate future.''
Commenting on this prediction, a spokesperson for GHLstockalert said, ''If you want to make huge profits, you must solve a huge problem.
Which is exactly what Anergen may be on the verge of doing as it begins clinical trials of its new arthritis drug candidate.
''The market is huge. Arthritis is second only to heart disease as a cause of work disability. It already results in 39 million doctor visits each
year and the number of people with arthritis is set to explode as the leading edge of the baby boomer generation enters the prime years of the
disease.
''Approximately 40 million Americans already suffer from arthritis and that number is expected to grow to 59.4 million according to a recent
report issued jointly by the National Institute of Health, the Center for Disease Control and Prevention (CDC), the Arthritis Foundation and the
American College of Rheumatology. More than 100 different diseases affecting the joints are classified as arthritis and the stiffness and pain
can often dramatically impede an individual's ability to function.
''Nobody can predict with precision the outcome of a clinical trial, but Anergen's state-of-the-art biotechnology research looks extremely
promising.
''So much so, in fact, Anergen is now teamed up with N.V. Organon, one of the pharmaceutical business units of Akzo Nobel headquartered
in The Netherlands. Akzo Nobel is a market-driven and technology based company that employs 70,000 people and is active in more than 60
countries with consolidated sales of 24.1 billion.
''In our judgment, collaboration between Akzo Nobel, with its enormous marketing and distribution network, and Anergen, with its team of
dedicated scientists and feverish pace of research, are the exact ingredients that can create a possible explosion in the share price of this tiny
but progressive bio-tech company.''
Is there any reason not to invest in this company? Yes. According to GHLstockalert, ''We could be wrong.''
|
